Clincosm LogoSign in Get a demo

Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic

Sponsor
University of California, San Francisco (Other)
Overall Status
Completed
CT.gov ID
NCT03783299
Collaborator
Center for Malariology, Parasitology, and Entomology (Other), The National Institute of Public Health (Other), Health Poverty Action (Other)
39,968
Enrollment
1
Location
2
Arms
13.1
Actual Duration (Months)
3056.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study assesses the effectiveness of targeted active case detection among high-risk populations in Southern Lao Peoples Democratic Republic (PDR). The investigators hypothesize that active case detection using the next generation of HRP-2 rapid diagnostic tests (RDTs) can help bridge gaps in identification of high-risk asymptomatic individuals with low density parasitemia, allowing for targeting of this reservoir and thereby reducing transmission. The investigators hypothesize that active case detection (testing and treating positive cases) with these RDTs will lead to a reduction in P. falciparum transmission.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

This study is the second phase of work in Champasak Province, Southern Lao PDR, building off a formative phase of work that characterized the demographics, occupations, migratory patterns, health-seeking behaviors, and social networks of mobile and migrant populations (MMPs) in four target districts. This phase of the study now aims to determine the effectiveness, cost-effectiveness, acceptability, and feasibility of proactive targeted test-and-treat activities using high-sensitivity malaria rapid diagnostic tests (HS-RDTs) for reducing Plasmodium falciparum malaria transmission in Champasak Province among (1) village residents and (2) mobile and migrant populations (MMPs) and other high-risk populations (HRPs).

The study will specifically assess the role of HS-RDTs, a diagnostic test that offers potentially ~10-fold greater sensitivity than standard RDTs, in active case detection at both the village-level and in forest-going HRPs for decreasing prevalence and incidence of P. falciparum in target areas. The effectiveness of these interventions will be compared independently and in combination against areas with no study interventions (standard of care) over the course of implementation (planned for October 2017 - November 2018).

The two main study interventions are mass test and treat (MTAT) using HS-RDTs in village-based populations, and peer navigator (PN) led focal test and treat (FTAT) using HS-RDTs in forest based HRPs. Primary outcomes will include PCR-based P. falciparum prevalence at endline. Following a baseline cross-sectional survey in November-December 2017, the interventions will consist of 3 rounds of MTAT spaced throughout the year, with potential to reduce to 2 based upon initial prevalence estimates, and ongoing FTAT by PNs among forest and forest-fringe HRPs, with the primary evaluation to be conducted through an end-line cross-sectional survey in November 2018.

Study Design

Study Type:
Interventional
Actual Enrollment :
39968 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Intervention Model Description:
The study is employing a split-plot community-randomized controlled trial design, with peer navigator test and treat randomized at the health center catchment level, and village-based test and treat randomized at the village level within health center catchment areas (HCCA).The study is employing a split-plot community-randomized controlled trial design, with peer navigator test and treat randomized at the health center catchment level, and village-based test and treat randomized at the village level within health center catchment areas (HCCA).
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Assessing the Effectiveness of Targeted Active Case Detection Among High Risk Populations in Southern Lao PDR
Actual Study Start Date :
Nov 28, 2017
Actual Primary Completion Date :
Nov 30, 2018
Actual Study Completion Date :
Dec 31, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Village-based MTAT

Intervention: For all households in intervention villages, after obtaining informed consent, MTAT will be conducted with all household members aged 18 months and older. The MTAT team will test each individual using both a standard RDT and HS-RDTs. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)

Diagnostic Test: Standard RDT and HS-RDT
All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
Other Names:
  • SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140
  • SD Bioline Pf/Pv RDT

    • Drug: Artemether-lumefantrine
    If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
    Other Names:
  • Coartem

    • Drug: Primaquine Phosphate
    If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
    Other Names:
  • Primaquine

    		•
    Experimental: Peer navigator-led FTAT

    Intervention: Peer navigators will actively seek non-village based HRPs in forested areas, rice fields and plantations, and any other non-permanent settlements within target health center catchment areas, and conduct FTAT among all consenting individuals. The Peer Navigators will test each individual using both a standard RDT and HS-RDT. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)

    Diagnostic Test: Standard RDT and HS-RDT
    All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
    Other Names:
  • SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140
  • SD Bioline Pf/Pv RDT

    • Drug: Artemether-lumefantrine
    If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
    Other Names:
  • Coartem

    • Drug: Primaquine Phosphate
    If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
    Other Names:
  • Primaquine

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Community-level PCR-based P. falciparum prevalence in sampled villages [4 months]

      This is defined as the proportion of individuals >18 months old with P. falciparum infection (detected by PCR) out of all individuals >18 months tested within the 2017 and 2018 surveys.The effectiveness of the interventions will be assessed as P. falciparum prevalence via PCR at end-line (post only) using generalized linear mixed effects models with separate random intercepts to allow for clustering within villages and health center catchments. The binomial distribution will be used to analyze prevalence outcomes (logistic regression)

    2. HS-RDT-based test positivity rate in village-based and forest-based samples [6 months]

      This is defined as the proportion of all individuals tested by HS-RDT at each round of the MTAT interventions or during routine FTAT, with a positive HS-RDT, among the population older than 18 months.The HS-RDT and RDT test positivity rates will be estimated for the MTAT villages during each intervention round. This will be done as soon as data on RDT and HS-RDT results are available, which would be expected to be one month following each round. Differences in prevalence measures at each round will be assessed using a χ2 test, as well as logistic regression models to account for potential confounding factors.

    3. Village-based population coverage of test and treat interventions [3 months]

      This indicator will be measured in two ways for each round of village MTAT. Operational program coverage is defined as the proportion of individuals ≥18 months old and households visited and offered the MTAT interventions within the target areas. Effective program coverage is defined as the proportion of individuals (≥18 months old) that agreed to participate in the MTAT intervention among all individuals ≥18 months old eligible to participate in the intervention in the target population

    4. Community-level confirmed P. falciparum malaria parasite incidence [1 year]

      This is defined as the number of total and confirmed outpatient (OPD) malaria confirmed and suspected cases per person per year for each village, as ascertained from the health facility registers, utilizing village population size estimates for the exposure denominator. Data pertaining to this outcome will be analyzed on an intention-to-treat basis. Monthly counts of confirmed malaria cases from the health facility registers will be linked to villages and analyzed in a time series Poisson or negative binomial model with random intercepts at the health center catchment and village levels.

    Secondary Outcome Measures

    1. Serology [2 months]

      Seropositivity to a panel of standard malaria parasite antigens for P. falciparum and P. vivax (including merozoite surface protein-1 (MSP-1) and apical membrane antigen-1 (AMA-1), will be used to examine both recent and medium-term exposures. These data will also be mapped used captured global positioning system (GPS) coordinates to examine serological hotspots. Finally, novel antigens will also be used to further explore any differences in parasite exposure between study arms. Vector exposure may also be explored using antigens to anopheline salivary proteins.

    2. Cost and cost effectiveness [12 months]

      For the costing portion of the study, the cost per case investigation conducted, cost per additional positive case identified using FTAT in village- and forest-based HRPs, and the cost per case actively detected per person screened during screen and treat. The cost-effectiveness of screen and treat will also be compared between village-based activities and peer-navigator led testing.

    3. Sensitivity and specificity of HS-RDTs [6 months]

      The P. falciparum prevalence from all individuals tested with HS-RDTs will be compared with parallel results from standard RDTs (all field testing activities) and to subsequent PCR-based testing (cross-sectional survey, FTAT and MTAT subset). In the latter case, the PCR-based result will serve as the gold standard for all comparisons. Sensitivity and specificity and receiver operating curve (ROC) analyses will be conducted to assess the performance of the HS-RDTs in field situations, and in the presence of mixed-species infections. DBS will be collected for cross-sectional survey, FTAT and MTAT.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Months and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    Village Based MTAT

    Inclusion Criteria

    • All household members 18 months of age and older.

    • Study participants include those in the 14 selected health center catchment areas within the four target districts in Champasak Province, Southern Lao PDR; Moulapamook, Panthampone, Sanamsaboun, and Soukhuma.

    • Members of households who have provided informed consent will be included for blood samples collection and treatment for identified malaria cases if meeting the appropriate criteria.

    Exclusion Criteria

    • Household members less than 18 months of age will be excluded.

    • Any individuals under the age of 18 months will be excluded from RDT testing and blood collection.

    Peer Naviagtor-Led FTAT

    Inclusion Criteria

    • All persons 15 years and older who have spent at least one night outside a formal village in the past one month.

    • Individuals must be 18 years and older and willing and able to provide consent to be included in the peer navigator or study staff focus group discussions and key informant interviews

    • Study participants include those in the 14 selected health center catchment areas within the four target districts in Champasak Province, Southern Lao PDR; Moulapamook, Panthampone, Sanamsaboun, and Soukhuma

    • High-risk populations in forested areas, rice field regions, plantations and any informal settlements

    • Individuals travelling into the HCCA who are willing and sufficiently able to communicate with PNs to assess their eligibility

    Exclusion criteria

    • Individuals under the age of 18 will be excluded from peer navigator or study staff focus group discussions and key informant interviews.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre for Marialogy, Parasitology, and Entomology Vientiane Lao People's Democratic Republic

    Sponsors and Collaborators

    • University of California, San Francisco
    • Center for Malariology, Parasitology, and Entomology
    • The National Institute of Public Health
    • Health Poverty Action

    Investigators

    • Principal Investigator: Adam Bennett, MA, PhD, University of California, San Francisco

    Study Documents (Full-Text)

    More Information

    Publications

    Responsible Party:
    University of California, San Francisco
    ClinicalTrials.gov Identifier:
    NCT03783299
    Other Study ID Numbers:
    • 17-22577
    • A124497
    First Posted:
    Dec 21, 2018
    Last Update Posted:
    Feb 23, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:
    Malaria, Falciparum
    Lumefantrine
    Artemether
    Primaquine
    Artemether, Lumefantrine Drug Combination

    Study Results

    No Results Posted as of Feb 23, 2021